282 related articles for article (PubMed ID: 18217957)
1. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C
Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957
[TBL] [Abstract][Full Text] [Related]
2. Helenalin suppresses essential immune functions of activated CD4+ T cells by multiple mechanisms.
Berges C; Fuchs D; Opelz G; Daniel V; Naujokat C
Mol Immunol; 2009 Sep; 46(15):2892-901. PubMed ID: 19656571
[TBL] [Abstract][Full Text] [Related]
3. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
Naujokat C; Berges C; Höh A; Wieczorek H; Fuchs D; Ovens J; Miltz M; Sadeghi M; Opelz G; Daniel V
Immunology; 2007 Jan; 120(1):120-32. PubMed ID: 17083604
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition.
An WG; Hwang SG; Trepel JB; Blagosklonny MV
Leukemia; 2000 Jul; 14(7):1276-83. PubMed ID: 10914553
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
van der Heijden JW; Oerlemans R; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Clin Exp Rheumatol; 2009; 27(1):92-8. PubMed ID: 19327235
[TBL] [Abstract][Full Text] [Related]
7. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells.
Nakamura T; Tanaka K; Matsunobu T; Okada T; Nakatani F; Sakimura R; Hanada M; Iwamoto Y
Int J Oncol; 2007 Oct; 31(4):803-11. PubMed ID: 17786311
[TBL] [Abstract][Full Text] [Related]
10. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells.
Berges C; Haberstock H; Fuchs D; Sadeghi M; Opelz G; Daniel V; Naujokat C
J Cell Biochem; 2009 Nov; 108(4):935-46. PubMed ID: 19735079
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
14. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.
Blanco B; Pérez-Simón JA; Sánchez-Abarca LI; Carvajal-Vergara X; Mateos J; Vidriales B; López-Holgado N; Maiso P; Alberca M; Villarón E; Schenkein D; Pandiella A; San Miguel J
Blood; 2006 May; 107(9):3575-83. PubMed ID: 16282346
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle- and activation-dependent regulation of cyclosporin A-induced T cell apoptosis.
Naujokat C; Daniel V; Bauer TM; Sadeghi M; Opelz G
Biochem Biophys Res Commun; 2003 Oct; 310(2):347-54. PubMed ID: 14521916
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells.
Straube C; Wehner R; Wendisch M; Bornhäuser M; Bachmann M; Rieber EP; Schmitz M
Leukemia; 2007 Jul; 21(7):1464-71. PubMed ID: 17495970
[TBL] [Abstract][Full Text] [Related]
19. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
Blanco B; Pérez-Simón JA; Sánchez-Abarca LI; Caballero-Velazquez T; Gutierrez-Cossío S; Hernández-Campo P; Díez-Campelo M; Herrero-Sanchez C; Rodriguez-Serrano C; Santamaría C; Sánchez-Guijo FM; Del Cañizo C; San Miguel JF
Haematologica; 2009 Jul; 94(7):975-83. PubMed ID: 19508976
[TBL] [Abstract][Full Text] [Related]
20. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
Issaenko OA; Amerik AY
Cell Cycle; 2012 May; 11(9):1804-17. PubMed ID: 22510564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
